Elevance's Profit Engine Isn't the Insurance Plan Anymore. It's Carelon.

Elevance's Carelon unit, its pharmacy and services businesses, generated roughly 71% of Q3 2026 segment operating gain on about 38% of gross segment revenue. Profit in the core Health Benefits plan fell 27.5%. A $6.99 adjusted EPS beat against a $4.70 consensus, a $29 full-year floor, and a $1B digital and AI push pulled the stock up 38.5% year over year.

ELV · Health Care · November 05, 2026

S&P 500 Position

Elevance sits in Managed Health Care alongside UnitedHealth, CVS Health (Aetna), Cigna and Humana, all vertically integrated insurers with PBM or services arms. The group trades as a bloc on policy and structural news. CVS's plan to split into two companies sent Elevance up 4% and Cigna up 3%. Political pressure on vertical integration, including Senator Warren's push to break up UnitedHealth, is the sector's biggest structural overhang for Carelon-style models.

Index Weight: Data unavailable | Rank: Data unavailable

Company Overview

Elevance Health is running a two-layer business. The insurance layer, Health Benefits, collects about $43B a quarter in premiums and fees and keeps very little of it. Q3 2026 operating gain was $436M on $43.4B of revenue, a margin of roughly 1%, and down 27.5% year over year. The services layer, Carelon, sits on top of that membership base and earns most of the money. CarelonRx made $616M of operating gain on $11.6B of revenue. Carelon Services made $292M on $7.7B, up 33.3%. Together Carelon produced about $0.9B of the company's $1.27B total segment operating gain, up 17%. Elevance is an integrated health-services platform with an insurance company attached as its largest customer. That structure explains the strategy. Elevance ended Q3 with about 44.9 million medical members. Growth in commercial fee-based accounts offset expected Medicaid attrition, and Medicare Advantage, Medicaid and Employer Group risk membership all declined. Management is choosing margin over enrollment. The Q3 medical loss ratio of 90.6% came in better than management expected, and the benefit expense ratio improved 70 basis points year over year. Premium yield, not member count, drove the $6.99 adjusted EPS print against a $4.70 consensus. Full-year adjusted EPS guidance now stands at no less than $29.00. The technically interesting piece is Carelon's data plumbing. Health OS, run by Carelon, joins provider data, lab results and pharmacy information into one platform. CEO Gail Boudreaux credits Health OS and related AI tools with cutting prior authorization denials by nearly 70%. The company has committed $1B across digital and AI capabilities. More than 60,000 employees already have internal AI productivity tools, and Elevance has an OpenAI partnership. Leadership has also changed: Carelon's president departed in May 2026, and CFO Mark Kaye now oversees the unit. The company's highest-margin asset now reports to its finance chief.

Products & Revenue

Q3 2026 total operating revenue was $50.44B, up 0.7%. Health Benefits accounts for most of the top line, but Carelon accounts for most of the profit. Segment revenue shares add to more than 100% because $12.23B of intercompany revenue is eliminated. Much of Carelon's pharmacy and services revenue comes from Elevance's own health plans. The profit mix is the real story: - CarelonRx produced 48.5% of segment operating gain ($616M, +10.8%), a 5.3% margin. - Carelon Services produced 23.0% ($292M, +33.3%), a 3.8% margin. - Health Benefits, at 86% of gross revenue, produced only 34.4% ($436M, -27.5%), about a 1.0% margin. Volume is slipping as plan membership shrinks. Adjusted scripts fell 2.8% to 82.6 million, and Carelon consumers served fell 6.8% to 91.0 million. Carelon's profit growth is therefore coming from mix and pricing, not volume.

Health Benefits (86.0%): Risk-based and fee-based medical plans across Commercial, Medicare Advantage, Medicaid, and the Federal Employee Program. FEP alone was $3.81B, down 7.0%. Q3 revenue was $43.36B (+2.6%), lifted by premium yield and service fees and partly offset by lower risk membership. It contributed 34.4% of operating gain.

CarelonRx (23.0%): The pharmacy benefit management and pharmacy services arm, handling 82.6 million adjusted scripts in Q3. Revenue was $11.60B (+5.5%), and it is the single largest profit contributor at $616M, or 48.5% of segment operating gain.

Carelon Services (15.3%): Clinical, behavioral, complex-care and data/analytics services, including the Health OS platform that links provider, lab and pharmacy data. Revenue was $7.71B (+5.2%), and operating gain jumped 33.3% to $292M.

Corporate & Other / Eliminations (-24.2%): Intercompany eliminations of $(12.23)B remove Carelon revenue earned from Elevance's own plans. Corporate & Other revenue was just $6M (down 96%), with a $(75)M operating loss.

Based on the Q3 2026 earnings release (quarter ended September 30, 2026; Business Wire/Morningstar, October 2026). Percentages are each segment's share of $50,440M total operating revenue. Shares sum to more than 100% before intercompany eliminations.

Leadership

Gail Boudreaux

CEO since 2017. Boudreaux has been President and CEO since 2017. She oversaw the build-out of Carelon as the company's profit center. On the April 2026 earnings call she framed a $1B investment across digital and AI capabilities as central to the operating model, citing more than 60,000 employees using internal AI tools. Her 2026 leadership reshuffle consolidated Health Benefits under one leader and put Carelon under the CFO. External speculation had named the departed Carelon president as her successor, so the shake-up also bears on succession.

Ratnakar Lavu, EVP & Chief Digital Information Officer: Lavu leads the Digital Platforms and Artificial Intelligence Office, the group executing the $1B digital and AI agenda. A secondary-source profile reports he joined from Nike in February 2024, bringing consumer-tech platform experience to a payer.

Ashok Chennuru, Chief Data & Digital AI Transformation Officer: Chennuru sits inside the Digital Platforms and AI Office spanning Elevance and Carelon. He owns the data foundation that platforms like Health OS depend on.

Mark Kaye, EVP & Chief Financial Officer; oversight of Carelon: Kaye took on Carelon oversight in February 2026, after Peter Haytaian stepped down as Carelon president effective May 4. He now controls the segment that generates about 71% of segment operating gain.

Felicia Norwood, Chief Health Benefits Officer: Norwood runs the combined Health Benefits organization. That is the $43B-a-quarter insurance engine whose margin compression, with operating gain down 27.5% in Q3, is management's most pressing problem.

Kristy Duffey, President, Carelon Health: Duffey joined in the April 2026 appointments to run Carelon Health, part of the services layer that grew operating gain 33.3% in Q3.

The AI Angle

AI as a claims-and-authorization operating system

Elevance's flagship AI story is Health OS, a Carelon-managed platform that combines provider data, lab results and pharmacy information. Boudreaux said on the April 22, 2026 earnings call that Health OS and related AI tools cut prior authorization denials by nearly 70%. That is the AI use case that matters most for a payer. Prior auth is where administrative cost, provider friction and medical-cost control collide. Reducing denials through earlier, data-complete submissions lowers rework on both sides and protects provider relationships without loosening utilization management. On infrastructure, Elevance runs a build-plus-partner model: - Buy: the company announced an OpenAI partnership on its Q3 2025 earnings call and launched an OpenAI-backed AI certification program for employees in September 2025. - Build: a secondary-source deployment profile describes an in-house internal AI platform called Spark and an internal chatbot running on multiple LLMs. - Rollout: the same profile reports an enterprise ChatGPT deployment beginning in February 2026. The multi-LLM design keeps Elevance from locking into a single model vendor while it standardizes on OpenAI for general productivity. The scale is real: more than 60,000 employees have access to internal AI productivity tools, inside a $1B commitment across digital and AI capabilities. The talent stack sits in the Digital Platforms and Artificial Intelligence Office. EVP and Chief Digital Information Officer Ratnakar Lavu leads it, with Ashok Chennuru as Chief Data & Digital AI Transformation Officer. Health OS lives in Carelon, which now reports to CFO Mark Kaye. As a result, the company's highest-leverage AI asset is governed by the executive most focused on unit economics. That raises the bar for ROI and lowers it for moonshots. The competitive edge comes from owning both the plan and the PBM and services layer, so Health OS sees medical, lab and pharmacy data in one place. The risk is concentration. AI in utilization management faces intense regulatory and public scrutiny across managed care. Carelon's profit leverage also depends on Elevance's own membership, which is contracting: consumers served fell 6.8% in Q3. AI efficiency gains have to outrun that volume decline.

Financial Snapshot

Revenue (TTM): $201.8B (TTM through September 30, 2026) | Net Income: $5.14B (TTM net income)

Margins: Gross: not meaningful for an insurer / data unavailable. Operating: about 2.5% (Q3 2026 segment operating gain of $1.27B on $50.44B revenue). Net: 2.5% (TTM).

Elevance runs a thin-margin, cash-generative model. It raised FY2026 operating cash flow guidance to at least $6.5B, and the Q3 MLR of 90.6% beat internal expectations. Capital return is steady: a $1.72 quarterly dividend (up from $1.71), roughly $2.3B of planned 2026 buybacks, and about $5.0B of authorization remaining. Buyback timing worked well: Q1 repurchases averaged $304.68 a share, against $398.75 in Q3 as the stock re-rated. No 2026 acquisition appears in the results.

1-Year Performance

$432.00, up 38.5% year over year.

The re-rating rests on earnings quality. Q3 adjusted EPS of $6.99 crushed the $4.70 consensus, revenue of $50.4B beat $49.32B, and full-year adjusted EPS guidance rose to at least $29.00. Margin discipline, through better MLR and pricing over membership, drove the beat. Sector catalysts added momentum: Elevance gained 4% on CVS's announced breakup.

Recent News

Fun Fact: Elevance's Q3 2026 intercompany eliminations totaled $12.23B, equal to about 63% of Carelon's $19.3B gross revenue. That implies most of Carelon's business is selling pharmacy and care services to Elevance's own health plans. Those internal transactions are where the profit concentrates. Carelon's 5% revenue growth produced 17% operating-gain growth even as scripts and consumers served declined.